- Home
- DSU vs FTRE Comparison
DSU vs FTRE Comparison
Compare DSU & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSU
- FTRE
- Stock Information
- Founded
- DSU 1998
- FTRE 1996
- Country
- DSU United States
- FTRE United States
- Employees
- DSU N/A
- FTRE N/A
- Industry
- DSU Finance Companies
- FTRE Medical Specialities
- Sector
- DSU Finance
- FTRE Health Care
- Exchange
- DSU Nasdaq
- FTRE Nasdaq
- Market Cap
- DSU 519.1M
- FTRE 469.0M
- IPO Year
- DSU N/A
- FTRE N/A
- Fundamental
- Price
- DSU $10.62
- FTRE $5.23
- Analyst Decision
- DSU
- FTRE Hold
- Analyst Count
- DSU 0
- FTRE 11
- Target Price
- DSU N/A
- FTRE $17.10
- AVG Volume (30 Days)
- DSU 148.2K
- FTRE 3.0M
- Earning Date
- DSU 01-01-0001
- FTRE 08-11-2025
- Dividend Yield
- DSU 10.06%
- FTRE N/A
- EPS Growth
- DSU N/A
- FTRE N/A
- EPS
- DSU N/A
- FTRE N/A
- Revenue
- DSU N/A
- FTRE $2,685,600,000.00
- Revenue This Year
- DSU N/A
- FTRE N/A
- Revenue Next Year
- DSU N/A
- FTRE $1.36
- P/E Ratio
- DSU N/A
- FTRE N/A
- Revenue Growth
- DSU N/A
- FTRE N/A
- 52 Week Low
- DSU $9.22
- FTRE $3.97
- 52 Week High
- DSU $11.40
- FTRE $28.41
- Technical
- Relative Strength Index (RSI)
- DSU 59.70
- FTRE 44.17
- Support Level
- DSU $10.36
- FTRE $5.11
- Resistance Level
- DSU $10.64
- FTRE $5.46
- Average True Range (ATR)
- DSU 0.08
- FTRE 0.38
- MACD
- DSU 0.01
- FTRE -0.04
- Stochastic Oscillator
- DSU 82.14
- FTRE 7.71
About DSU Blackrock Debt Strategies Fund Inc.
Blackrock Debt Strategies Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income by investing in a diversified portfolio of U.S. companies' debt instruments including corporate loans. The fund's secondary investment objective is to provide capital appreciation.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.